Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives

Panthi, Vijay Kumar; Fairfull-Smith, Kathryn E.; Islam, Nazrul

doi:10.1016/j.jddst.2024.105517

Cited by 2 publications

(1 citation statement)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lower respiratory tract infections (LRTIs) pose life-threatening risks and can significantly affect health and the economy. Conditions such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and bronchiectasis are commonly linked to LR-TIs [1,2]. The primary agents behind these infections are diverse and include contagious bacteria of both Gram-positive and Gram-negative types, such as Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Burkholderia species [3,4].…”

Section: Introductionmentioning

confidence: 99%

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Panthi,

Fairfull-Smith,

Islam

2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Inhaled ciprofloxacin (CFX) has been investigated as a treatment for lower respiratory tract infections (LRTIs) associated with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and bronchiectasis. The challenges in CFX effectiveness for LRTI treatment include poor aqueous solubility and therapy resistance. CFX dry powder for inhalation (DPI) formulations were well-tolerated, showing a remarkable decline in overall bacterial burden compared to a placebo in bronchiectasis patients. Recent research using an inhalable powder combining Pseudomonas phage PEV20 with CFX exhibited a substantial reduction in bacterial density in mouse lungs infected with clinical P. aeruginosa strains and reduced inflammation. Currently, studies suggest that elevated biosynthesis of fatty acids could serve as a potential biomarker for detecting CFX resistance in LRTIs. Furthermore, inhaled CFX has successfully addressed various challenges associated with traditional CFX, including the incapacity to eliminate the pathogen, the recurrence of colonization, and the development of resistance. However, further exploration is needed to address three key unresolved issues: identifying the right patient group, determining the optimal treatment duration, and accurately assessing the risk of antibiotic resistance, with additional multicenter randomized controlled trials suggested to tackle these challenges. Importantly, future investigations will focus on the effectiveness of CFX DPI in bronchiectasis and COPD, aiming to differentiate prognoses between these two conditions. This review underscores the importance of CFX inhalable formulations against LRTIs in preclinical and clinical sectors, their challenges, recent advancements, and future perspectives.

show abstract

Section: Introductionmentioning

confidence: 99%

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Panthi,

Fairfull-Smith,

Islam

2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

Application of Nanobiomedicine in Acute Lung Injury

Lei,

Wang,

Yin

et al. 2024

j biomater tissue eng

View full text Add to dashboard Cite

The respiratory system plays a crucial role in human life activities, and acute lung injury (ALI) is a highly fatal respiratory disease caused by a variety of reasons. At present, although several preclinical studies have demonstrated the efficacy of pharmacological interventions, supportive care and mechanical ventilation still remain the primary modalities for managing ALI, there are still no safe and effective treatments for ALI. With the rapid development of nanotechnology, a variety of nanobiomedicines with different structures and functional moieties have been well-designed based on their targeting ability and the pathophysiology of ALI. In this review, it summarizes the challenges faced by ALI therapy, introduces nanobiomedicines including liposomes, polymers, inorganic materials, and others to bring effective therapeutic effects for ALI, and discusses the research progress in recent years based on nanobiomedicine applied to acute lung injury. Finally, it provides a summary and prospect on the application of nanobiomedicine in ALI.

show abstract

Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives

Cited by 2 publications

References 171 publications

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Application of Nanobiomedicine in Acute Lung Injury

Contact Info

Product

Resources

About